Tag: CareDx

Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

First Pediatric Study to Evaluate Use of AlloSure dd-cfDNA as Biomarker for Allograft BK Infection Findings Add to Growing Body of Evidence Showing Clinical Value of AlloSure for Surveillance in Pediatric Kidney Transplant Patients BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and…

Continue Reading Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

Cell-Free DNA Testing Market – Lord Web

Welcome to our community, we want you capitalize from Cell-Free DNA Testing Market and are fortunate to go to you web site, you possibly can succeed know-how tradition and craft on our web site 24 hours, we proffer you followers the most recent world advice across the clock . …

Continue Reading Cell-Free DNA Testing Market – Lord Web

Patents on Measuring cfDNA to Detect Rejection of Transplanted Organs Held Invalid | Insights

When a person who has received an organ transplant experiences rejection, DNA from the transplanted organ is released into the bloodstream as the organ’s cells are attacked by the person’s immune system. The circulating DNA from the transplanted organ — referred to as cell-free DNA (cfDNA) — can be distinguished…

Continue Reading Patents on Measuring cfDNA to Detect Rejection of Transplanted Organs Held Invalid | Insights

CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting

CareDx, Inc. Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interventions CareDx Symposia Feature Latest Advancements Including XenoSure and XenoMap SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) –…

Continue Reading CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting

NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — CareDx, Inc.,  (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a study led by the National Institutes of…

Continue Reading NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection